As the intestinal epithelium is replaced every week, maintenance of this tissue requires rapid self-renewal that is driven by intestinal stem cells. This homeostasis is disrupted in a number of settings, including allogeneic bone marrow transplantation. After allogeneic bone marrow transplantation, allogeneic T cells often attack and kill intestinal cells in an interferon-γ (IFNγ)–dependent…
Sickle cell disease is a life-threatening haematological condition described as the most neglected global health problem today. There are enough data to show the enormous…
Learn about St. Jude research showing that bone marrow transplantation to treat sickle cell disease can improve heart damage such as myocardial fibrosis.
Sickle cell disease is a life-threatening haematological condition described as the most neglected global health problem today. There are enough data to show the enormous…
The paradigm of sickle cell disease management is rapidly evolving with exciting new advances in transplant and genetic therapies. Are you ready for these changes?…
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
